FDA Approves EPYSQLI — Teva Pharmaceuticals USA, Inc.

Teva Pharmaceuticals USA has secured FDA approval for EPYSQLI (eculizumab-aagh) for intravenous administration, a move expected to intensify competitive intensity in the PNH market by offering an alternative administration route. This approval represents a direct challenge to current pricing momentum and market share held by legacy competitors like CSL Behring and Biogen.